Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New genetic tool could unmask mystery brain infections in the tropics

NCT ID NCT07251049

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether next-generation sequencing can identify the infectious germs causing severe brain (encephalitis) and spinal cord (myelitis) inflammation in 100 patients in Guadeloupe. Many cases currently have no known cause. By analyzing spinal fluid, researchers hope to discover new or emerging pathogens specific to the tropics. This is an observational study, not a treatment, but could improve future diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify unknown or emerging germs that cause severe brain infections, leading to better diagnosis and treatment in tropical regions.
What could go wrong
This is an observational study, not a treatment trial. It may not find new pathogens, and results may not apply to other populations or regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with suspected acute infectious encephalitis and / or myelitis, according to the clinical and paraclinical criteria described in recommendations of the International Encephalitis Consortium in 2013 and the by the Transverse Myelitis Consortium Working Group in 2002

Ages

28 days and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * We selected the following eligibility criteria for patients with acute encephalitis: * Patient of at least 28 days of life * With acute onset of symptoms for more than 24 hours * A major criterion among the following: * a disorder of consciousness or alertness * memory disorder * lethargy * modification of personal or behavioral disorder, irritability * confusion, disorientation in time or space \- At least two of the following minor criteria: * temperature above 38 ° C * new onset focal neurological deficit * epileptic crisis * biological abnormality of CSF (≥ 5 Leukocytes / mm3, protein ≥ 0.40 g / L) * partial or general epileptic seizure (s) not attributable to pre-existing epileptic disease and / or a recent focal neurological symptom * brain imaging suggestive of encephalitis, with EEG abnormalities suggestive of encephalitis * And absence of alternative diagnosis (intoxication, metabolic encephalopathy) * Persons affiliated or benefiting from a social security scheme; * Having given free, informed, written and signed consent by the patient or his legal representative (no later than the day of inclusion and prior to any review required by the research); * Eligibility criteria for Acute Transverse Myelitis Patients: * Patient of at least 28 days of life * Acute onset of symptoms for more than 24 hours * Medullary focal abnormality, responsible for motor, sensory or autonomic symptoms * contrast enhancement on bone marrow MRI and / or abnormal CSF (≥ 5GB / mm3, protein uptake ≥ 0.40 g / L) * Evolution between nadir and maximum symptoms, less than 4 weeks * Persons affiliated or benefiting from a social security scheme; * Having given free, informed, written and signed consent by the patient or his legal representative (no later than the day of inclusion and prior to any review required by the research); Exclusion Criteria: * Primary vasculitis of the central nervous system or a documented specific impairment in an autoimmune condition * Cerebral thrombophlebitis if not associated with encephalitis * Meningitis without clinical or paraclinical argument for cerebral parenchymal involvement * Pyogenic abscess * Cerebral or spinal abscess * Tumoral or hematological pathology of the central nervous system * Toxic or metabolic encephalopathy * Transverse myelitis with vascular or traumatic origin * Known chronic infection with HTLV virus

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute encephalitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de la Guadeloupe

    RECRUITING

    Pointe-à-Pitre, Guadeloupe, 97159, Guadeloupe